CLDN18 and gastric cancer: The CCK-8 assay confirmed that CLDN18-ARHGAP26/42 fusion can promote the ability of paclitaxel to inhibit the proliferation of GC cells, while these fusions had no significant effect on oxaliplatin inhibition of GC cell proliferation (Fig. 6c).